Moderna to supply EU up to 160M COVID vaccine doses

 

• The European Union has struck a deal with U.S. biotech firm Moderna (NASDAQ:MRNA) for the supply of as many as 160M doses of its experimental COVID-19 vaccine, European Commission President Ursula von der Leyen said today.
• Last week, Moderna said its experimental vaccine was 94.5% effective in preventing COVID-19, based on interim data from a late-stage clinical trial.
• Actual purchases will be carried out by EU governments if the vaccine is approved by the EU's drug regulator.
• Contract terms have not been disclosed: An EU official involved in the talks has told Reuters that the EU was seeking a price below $25 per dose for the Moderna vaccine, but Moderna CEO Stephane Bancel said on Sunday the company would charge governments in the $25-$37/dose range, depending on the amount ordered.
• The Moderna supply deal is the sixth the EU has negotiated with COVID-19 vaccine makers AstraZeneca, Pfizer-BioNTech, Sanofi-GSK, Johnson & Johnson and CureVac - and takes the total number of doses secured by the bloc to 1.96B for its ~450M population, and the EU is in talks with Novavax for a seventh vaccine.
• https://seekingalpha.com/news/3639287-moderna-to-supply-eu-up-to-160m-covid-vaccine-doses